Pyronaridine-artesunate retreatment for malaria  by Bélard, Sabine & Kurth, Florian
Comment
136 www.thelancet.com/infection   Vol 16   February 2016
6 Grigg MJ, William T, Menon J, et al. Artesunate–meﬂ oquine versus 
chloroquine for treatment of uncomplicated Plasmodium knowlesi 
malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. 
Lancet Infect Dis 2015; published online Nov 18. http://dx.doi.org/10.1016/
S1473-3099(15)00415-6.
7 Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM. Limitations of microscopy 
to diﬀ erentiate Plasmodium species in a region co-endemic for Plasmodium 
falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J 2013; 12: 8.
8 WHO. Guidelines for the treatment of malaria. Geneva: World Health 
Organization, 2015.
9 Malaysian Ministry of Health. Management guidelines of malaria in Malaysia. 
Vector Borne Disease Sector, Disease Control Division, Ministry of Health, 
Malaysia, in Cooperation with Health Education Division, 2013. 
10 Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure 
associated with a triple mutant including kelch13 C580Y in Cambodia: 
an observational cohort study. Lancet Infect Dis 2015; 15: 683–91.
11 Lau YL, Fong MY, Mahmud R, et al. Speciﬁ c, sensitive and rapid detection of 
human Plasmodium knowlesi infection by loop-mediated isothermal 
ampliﬁ cation (LAMP) in blood samples. Malar J 2011; 10: 197.
12 NanoMal. The NanoMal Project. www.nanomal.org (accessed Nov 1, 2015).
13 Hede M, Okorie P, Fruekilde S, et al. Reﬁ ned method for droplet 
microﬂ uidics-enabled detection of Plasmodium falciparum encoded 
topoisomerase i in blood from malaria patients. Micromachines 2015; 
6: 1505–13.
Michael Ramharter
Department of Medicine I, Division of Infectious Diseases and 
Tropical Medicine, Medical University of Vienna, Vienna, Austria; 
and Institut für Tropenmedizin, University of Tübingen, Tübingen, 
Germany
michael.ramharter@meduniwien.ac.at
I declare no competing interests.
1 Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in 
humans is widely distributed and potentially life threatening. Clin Infect Dis 
2008; 46: 165–71.
2 William T, Jelip J, Menon J, et al. Changing epidemiology of malaria in 
Sabah, Malaysia: increasing incidence of Plasmodium knowlesi. Malar J 
2014; 13: 390.
3 Millar SB, Cox-Singh J. Human infections with Plasmodium 
knowlesi-zoonotic malaria. Clin Microbiol Infect 2015; 21: 640–48.
4 Ramharter M, Wernsdorfer WH, Kremsner PG. In vitro activity of 
quinolines against Plasmodium falciparum in Gabon. Acta Trop 2004; 
90: 55–60.
5 Kurth F, Pongratz P, Bélard S, Mordmüller B, Kremsner PG, Ramharter M. 
In vitro activity of pyronaridine against Plasmodium falciparum and 
comparative evaluation of anti-malarial drug susceptibility assays. 
Malar J 2009; 8: 79.
Pyronaridine-artesunate retreatment for malaria
In The Lancet Infectious Diseases, Issaka Sagara and 
colleagues1 report a large trial of the safety and eﬃ  cacy of 
repeated administration of pyronaridine-artesunate, a 
novel artemisinin combination therapy (ACT) for un com-
plicated malaria. ACTs are the therapeutic cornerstone 
of malaria control and have contributed to reducing the 
global malaria burden substantially. The aim to expand the 
range of partner drugs for combination with artemisinin 
derivatives and continued eﬀ orts to optimise eﬃ  cacy, 
tolerability, costs, and treatment regimens led to the 
development of the pyronaridine-artesunate combination.
About 15 years ago pyronaridine, an antimalarial 
drug ﬁ rst synthesised in the 1970s,2 entered clinical 
testing in combination with artesunate under 
the lead of a public–private product development 
partnership between Shin Poong Pharmaceutical 
Company and Medicines for Malaria Venture. This novel 
ACT showed excellent eﬃ  cacy against Plasmodium 
falciparum malaria in a series of phase 2 and 3 studies3 
and, noteworthy, was systematically assessed for 
treatment of Plasmodium vivax malaria.4 In 2012, 
pyronaridine-artesunate was granted a positive 
scientiﬁ c opinion by the European Medicines Agency 
under Article 58 and added to WHO’s list of prequaliﬁ ed 
medicines. However, because of in suﬃ  cient clinical trial 
data at that time and concerns about drug-induced 
hepatotoxicity, the recommended indication was 
restricted to a single treatment course.
Drug-induced liver injury is one of the most common 
reasons for failure of new compounds during clinical 
development and for withdrawal from the market.5 
Generally, either an intrinsic (dose-dependent injury—eg, 
through accumulation of the drug or reactive metabolites) 
or idiosyncratic mechanism (metabolic or immunoallergic 
injury through re-exposure after initial sensitisation) is 
postulated in drug-induced liver injury. The long half-
life of artemisinin partner drugs with their inherent risk 
of accumulation and the need for repeated antimalarial 
treatment in endemic regions clearly emphasise the 
necessity of retreatment trials. 
The prospective multicentre randomised trial by 
Sagara and colleagues1 compared safety and eﬃ  cacy of 
pyronaridine-artesunate tablet or granule formulation 
after a ﬁ rst malaria treatment episode versus retreatment 
in children and adults. Artemether-lumefantrine was 
the comparator treatment. The primary safety outcome 
was the incidence of post-treatment hepatotoxicity. 
About a third of 1015 pyronaridine-artesunate-treated 
patients were retreated in this study. Neither an increase 
in the frequency nor severity of hepatotoxicity events, 
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or in other adverse events was noted after retreatment 
compared with ﬁ rst treatment episodes. Overall, the 
incidence of hepatotoxicity events was about 1% in 
both groups and all events resolved without sequelae. 
The investigators concluded that safety and eﬃ  cacy of 
pyronaridine-artesunate were similar with ﬁ rst treatment 
versus retreatment of malaria and that these ﬁ ndings lend 
support for the wider use of pyronaridine-artesunate.
Close active follow-up for 6 weeks after treatment, 
monthly home visits thereafter, and provision of health 
care 24 h per day by the study team despite the long study 
period in a challenging geographical setting, and the large 
sample size of retreated patients are important strengths 
of the study. A more comprehensive diagnostic work 
up of diﬀ erential diagnoses underlying hepatotoxicity 
could have further strengthened the main conclusion of 
this trial. The unintended retreatment of four patients 
with hepatotoxic events after the ﬁ rst treatment episode 
(who should have been excluded from retreatment in 
this study) provides further reassurance because none 
of the patients showed any symptoms of recurrence or 
exacerbation of hepatotoxicity. 
Although the overall results of this study are highly 
reassuring, some concerns remain at this stage of the 
clinical development of pyronaridine-artesunate: most 
importantly, the exclusion of patients with liver diseases, 
increases in liver enzymes, or HIV infection in the phase 
2 and 3 trials. Moreover, few data are available for very 
small children. However, these patients constitute 
important target populations for the treatment of malaria 
in endemic regions. Co-medication such as antiretroviral 
treatment and use of traditional herbal medicine might 
interfere with any new antimalarial drug and should 
therefore be assessed further. These important concerns 
need to be addressed in further clinical phase 3 trials or in 
post-marketing surveillance.
More evidence for the safety of pyronaridine-
artesunate in susceptible populations will promote 
the exploitation of the many beneﬁ ts of pyronaridine-
artesunate. A ﬁ xed-dose once-daily regimen including 
the availability of a granule formulation for children,6 
the absence of a major eﬀ ect of food intake on 
bioavailability, a long shelf life, a long post-treatment 
prophylactic eﬀ ect, and projected low price lend support 
to pyronaridine-artesunate becoming a powerful new 
arrow in the quiver for the ﬁ ght against malaria.
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Tackling neglect: treating schistosomiasis in pregnancy
Schistosomiasis is a major neglected tropical disease 
caused by blood ﬂ ukes of the genus Schistosoma and 
transmitted through intermediate snail hosts. It aﬀ ects 
African, Asian, and South American populations, often 
in remote communities, such as ﬁ shing villages accessed 
only by water.1 Among these neglected communities, 
women of reproductive age (and their unborn children) 
have been further neglected due to recommendations 
that praziquantel treatment be avoided during pregnancy 
and lactation. 
In The Lancet Infectious Diseases, Remigio Olveda and 
colleagues2 address this neglected area for Schistosoma 
japonicum in the Philippines. As they explain, despite 
the WHO 2002 recommendation that pregnant and 
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